文献速递胸部肿瘤

染色体非整倍体检测在肺癌高危人群中的临床价值

Clinical Utility of Chromosomal Aneusomy in Individuals at High Risk of Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2017-06-19

本研究通过四项嵌套病例对照研究回顾性评估痰液荧光原位杂交检测染色体非整倍体(CA-FISH)的价值。高危队列中敏感度0.67、特异度0.94、阳性似然比11.66;筛查队列中敏感度0.20、特异度0.84、阳性似然比1.36。高危 settings 下CA-FISH可作为低剂量CT的辅助手段,但筛查场景临床应用受限。

要点

  • 高危队列痰液CA-FISH阳性似然比11.66,可作为低剂量CT辅助手段。
  • 筛查队列阳性似然比1.36,临床应用价值有限。
  • 科罗拉多肺结节生物标志物试验正在前瞻性评估CA-FISH。

核心结论

  • 痰液CA-FISH的高阳性似然比表明其在高危 settings 下可作为低剂量CT筛查肺癌的辅助手段。
  • 在筛查场景中,其低阳性似然比限制了临床应用价值。

研究设计与样本

  • 回顾性纵向评估,纳入四项嵌套病例对照研究,评估痰液荧光原位杂交检测染色体非整倍体(CA-FISH)。
  • 受试者工作特征分析形成两个分组队列:高危队列(科罗拉多高危队列和科罗拉多结节队列,68例病例和69例对照)和筛查队列(美国放射学会影像网络/国家肺癌筛查试验和匹兹堡肺筛查研究,97例病例和185例对照)。
  • CA-FISH检测为四靶点DNA面板,涵盖EGFR和v-myc禽骨髓细胞瘤病毒癌基因同源物(MYC)基因、5p15和着丝粒6区域,或成纤维细胞生长因子1基因(FGFR1)和磷脂酰肌醇-4,5-二磷酸3-激酶催化亚基α基因(PIK3CA)。
  • 采用四分类量表(正常、可能正常、可能异常、异常)。

主要发现

  • 高危参与者敏感度为0.67(95%CI:0.55-0.78),特异度为0.94(95%CI:0.85-0.98)。
  • 筛查参与者敏感度为0.20(95%CI:0.13-0.30),特异度为0.84(95%CI:0.78-0.89)。
  • 高危参与者阳性似然比为11.66(95%CI:4.44-30.63),阴性似然比为0.34(95%CI:0.24-0.48)。
  • 筛查参与者阳性似然比为1.36(95%CI:0.81-2.28),阴性似然比为0.93(95%CI:0.83-1.05)。

关键数值与推荐

  • 高危参与者敏感度0.67(95%CI:0.55-0.78),特异度0.94(95%CI:0.85-0.98)。
  • 筛查参与者敏感度0.20(95%CI:0.13-0.30),特异度0.84(95%CI:0.78-0.89)。
  • 高危参与者阳性似然比11.66(95%CI:4.44-30.63),阴性似然比0.34(95%CI:0.24-0.48)。
  • 筛查参与者阳性似然比1.36(95%CI:0.81-2.28),阴性似然比0.93(95%CI:0.83-1.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Low-dose computed tomography screening for lung cancer has a high false-positive rate with frequent discovery of indeterminate pulmonary nodules. Noninvasive biomarkers are needed to reduce false positives and improve risk stratification. A retrospective longitudinal evaluation was performed to assess chromosomal aneusomy in sputum by fluorescence in situ hybridization (CA-FISH) in four nested case-control studies. METHODS: Receiver operating characteristic analysis resulted in two grouped cohorts: a high-risk cohort (Colorado High-Risk Cohort and Colorado Nodule Cohort [68 case patients and 69 controls]) and a screening cohort (American College of Radiology Imaging Network/National Lung Screening Trial and Pittsburgh Lung Screening Study [97 case patients and 185 controls]). The CA-FISH assay was a four-target DNA panel encompassing the EGFR and v-myc avian myelocytomatosis viral oncogene homolog (MYC) genes, and the 5p15 and centromere 6 regions or the fibroblast growth factor 1 gene (FGFR1) and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA). A four-category scale (normal, probably normal, probably abnormal, and abnormal) was applied. Sensitivity, specificity, and positive and negative likelihood ratios (LRs) (with 95% confidence intervals [CIs]) were estimated for each cohort. RESULTS: Sensitivity and specificity were, respectively, 0.67 (95% CI: 0.55-0.78) and 0.94 (95% CI: 0.85-0.98) for high-risk participants and 0.20 (95% CI: 0.13-0.30) and 0.84 (95% CI: 0.78-0.89) for screening participants. The positive and negative LRs were, respectively, 11.66 (95% CI: 4.44-30.63) and 0.34 (95% CI: 0.24-0.48) for high-risk participants and 1.36 (95% CI: 0.81-2.28) and 0.93 (95% CI: 0.83-1.05) for screening participants. CONCLUSION: The high positive LR of sputum CA-FISH indicates that it could be a useful adjunct to low-dose computed tomography for lung cancer in high-risk settings. For screening, however, its low positive LR limits clinical utility. Prospective assessment of CA-FISH in the incidentally identified indeterminate nodule setting is ongoing in the Colorado Pulmonary Nodule Biomarker Trial.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Barón AE, Kako S, Feser WJ, et al. Clinical Utility of Chromosomal Aneusomy in Individuals at High Risk of Lung Cancer. J Thorac Oncol. 2017. PMID: 28634123. doi:10.1016/j.jtho.2017.06.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。